

October 29, 2015



Atara Biotherapeutics Announces Participation in Three Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its participation in three upcoming investor conferences:

- **The 2015 Citi Global Healthcare Conference at the New York Palace in New York City on Thursday, November 5, 2015.** Isaac Ciechanover, President and CEO of Atara Bio and John McGrath, CFO of Atara Bio, will host meetings with investors during this conference.
- **The Goldman Sachs U.S. Emerging / SMID Cap Growth Conference 2015 at the Crowne Plaza Times Square on Thursday, November 19.** Gad Soffer, COO of Atara Bio, will present at 1:10 PM ET and Gad Soffer and Chris Haqq, M.D., CMO of Atara Bio will also host meetings with investors.
- **The Jefferies Autumn 2015 Global Healthcare Conference at the May Fair Hotel in London on Thursday, November 19.** Isaac Ciechanover, President and CEO of Atara Bio, is scheduled to present at 5:20 PM GMT, and will also host meetings with investors.

Live webcasts of the presentations at the Goldman Sachs and Jefferies conferences will be available by visiting the Investors section of the Atara Bio website at www.atarabio.com. Archived replays of these webcasts will be available on the Company's website for 14 days following the conferences.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation. Atara Bio's programs include molecularly targeted product candidates and T-cell product candidates. Molecularly targeted product candidates include PINTA 745, STM 434 and ATA 842. These product candidates target myostatin and activin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications. T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL.

INVESTOR & MEDIA CONTACT:
Tina Gullotta
Atara Biotherapeutics, Inc.
650-741-1613

tgullotta@atarabio.com

Source: Atara Biotherapeutics, Inc.